Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia.
http://www.ncbi.nlm.nih.gov/pubmed/19927363
Archivi categoria: Pubblicazioni
Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study.
http://www.ncbi.nlm.nih.gov/pubmed/20091936
Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia.
The effect of lipoprotein apheresis (Direct Adsorption of Lipids, DALI) (LA) on plasma levels of pentraxin 3 (PTX3), an inflammatory marker that reflects coronary plaque vulnerability, and expression of PTX3 mRNA was evaluated in patients with hyperLp(a)lipoproteinemia and angiographically defined atherosclerosis/coronary artery disease. Eleven patients, aged 55 ± 9.3 years …
New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
http://www.ncbi.nlm.nih.gov/pubmed/22963620
Lipoprotein apheresis: state of the art and novelties
http://www.ncbi.nlm.nih.gov/pubmed/23357136
Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances
http://www.ncbi.nlm.nih.gov/pubmed/25410046
Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
http://www.ncbi.nlm.nih.gov/pubmed/25881720
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.
http://www.ncbi.nlm.nih.gov/pubmed/25965722
Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.
http://www.ncbi.nlm.nih.gov/pubmed/25950706
Ipercolesterolemia Familiare “Oggi possiamo intervenire efficacemente in età pediatrica”
“L’ipercolesterolemia familiare – spiega la dottoressa Guardamagna, pediatra dell’Università di Torino – è una condizione ereditaria che si correla con un elevato rischio di eventi cardiovascolari che si manifestano di solito in età adulta, anche se il soggetto non ha in precedenza manifestato sintomi specifici. Diverso il caso dei soggetti …